

**SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION**

1. LICENSEE/LOCATION INSPECTED:  Hurley Medical Center Department of Radiology One Hurley Plaza Flint, MI 48503  REPORT NUMBER(S) 2012-001		2. NRC/REGIONAL OFFICE  Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352	
3. DOCKET NUMBER(S)  030-01993	4. LICENSE NUMBER(S)  21-00338-02	5. DATE(S) OF INSPECTION  October 15, 2012	

**LICENSEE:**

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

- 1. Based on the inspection findings, no violations were identified.
- 2. Previous violation(s) closed.
- 3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, to exercise discretion, were satisfied.

\_\_\_\_\_ Non-cited violation(s) were discussed involving the following requirement(s):

- 4. During this inspection, certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited in accordance with NRC Enforcement Policy. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.  
(Violations and Corrective Actions)

**Statement of Corrective Actions**

I hereby state that, within 30 days, the actions described by me to the Inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

TITLE	PRINTED NAME	SIGNATURE	DATE
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	Deborah A. Piskura, Health Physicist	<i>Deborah A. Piskura</i>	10/15/12
BRANCH CHIEF	Tamara E. Bloomer, Chief, MIB	<i>Tamara Bloomer</i>	10/24/12

**Docket File Information**  
**SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION**

1. LICENSEE/LOCATION INSPECTED:  Hurley Medical Center Department of Radiology One Hurley Plaza Flint, MI 48503  REPORT NUMBER(S) 2012-001	2. NRC/REGIONAL OFFICE  Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352
---	---

3. DOCKET NUMBER(S)  030-01993	4. LICENSE NUMBER(S)  21-00338-02	5. DATE(S) OF INSPECTION  October 15, 2012
--------------------------------------	---	--

6. INSPECTION PROCEDURES USED  87130, 87131, 87133	7. INSPECTION FOCUS AREAS  03.01 - 03.07
--	--

**SUPPLEMENTAL INSPECTION INFORMATION**

1. PROGRAM CODE(S)  02240	2. PRIORITY  2	3. LICENSEE CONTACT  Apparao Mukkamala, M.D., RSO	4. TELEPHONE NUMBER  (810) 257-9000
---------------------------------	----------------------	---	---

Main Office Inspection      Next Inspection Date: Oct. 2014

Field Office Inspection

Temporary Job Site Inspection

**PROGRAM SCOPE**

This licensee was a community medical center, authorized to use licensed material permitted by Sections 35.100, 35.200, 35.300, and 35.1000 limited to the I-125 GlioSite therapy system. The nuclear medicine department was staffed with one full-time technologist and one PRN who performed approximately 75+ diagnostic nuclear medicine procedures per month. The licensee received unit doses from a licensed radiopharmacy. The hospital performed a full spectrum of nuclear diagnostic imaging studies. Typically, in a year the hospital administered 3-6 iodine-131 thyroid carcinoma therapies, 20-25 hyperthyroidism treatments, and 5-6 whole body CA follow up studies. The hospital obtained its I-131 in capsule form only. All patients were released in accordance with Section 35.75. No beta radiopharmaceutical therapies were administered since the previous inspection. Although authorized to administer GlioSite therapy, the licensee had not used this material to date. The licensee retained the services of a consulting physicist to audit the radiation safety program on a quarterly basis.

This inspection consisted of interviews with licensee personnel, a review of selected records, a tour of the nuclear medicine department, and independent measurements. The inspector observed licensee nuclear medicine personnel prepare, assay and administer two unit doses for cardiac imaging procedures. The inspection included observations of security of byproduct material, use of personnel monitoring, and dose calibrator QA checks.